Global Neurasthenia Treatment Market – Industry Trends and Forecast to 2030

Neurasthenia Treatment Market Analysis and Size

Rise in the incidence of posterior vaginal prolapse will elevate the market growth, changing lifestyle of the people, increase in the lack of physical work and rise in the government support for R&D are some of the vital factors among others driving the neurasthenia treatment market. Several patients with neurasthenia present with the predominant compliant of physical and mental fatigue, aggravated by exertion. They commonly have symptoms of depression and anxiety, but mostly fatigue is predominant.

Data Bridge Market Research analyses a growth rate in the neurasthenia treatment market in the forecast period 2023-2030. The expected CAGR of neurasthenia treatment market is tend to be around 5.90% in the mentioned forecast period. The market was valued at USD 100 million in 2022, and it would grow upto USD 158.19 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Neurasthenia Treatment Market Scope and Segmentation

Market Definition

Neurasthenia is a neurological condition characterized by cell destruction that produces myelin. Myelin is a sticky material that supports nerve cells, in the brain and spinal cord, also known as white matter of the central nervous system. In healthy individuals, the JCV virus remains inactive leading to this dreadful disease only when the immune system is compromised. Major symptoms include problems with vision, balance, coordination, speech, and thinking.

Neurasthenia Treatment Market Dynamics

Drivers

• Increasing Prevalence of Fatigue

Fatigue is prevalent in the general population, but the diagnosis of neurasthenia is lesser. A study found that although 13% of the population complain of prolonged and excessive fatigue, but less than 2% met ICD-10 criteria for neurasthenia, and less than 0.5% neurasthenia without comorbid anxiety and depression. Neurasthenia is more common in women.

• Rising R&D Activities By Market Players

Growing emphasis on the R&D of drugs and therapies for rare diseases creates a huge opportunity for the market. Several companies are trying to innovative therapies aimed at control of the condition instead of improving immunity, projected to increase the growth of the neurasthenia treatment market during the forecast period.

Opportunities

• Varied Treatment Methods

There are various treatment processes that create many opportunities for the diseased condition. Several studies suggest that antidepressant treatments are of limited value, but there is good evidence for rehabilitative psychological treatments, including CBT and simple graded exercise therapy.

• Increasing Rates of Depression

About 17.3 million people were suffering from major depressive episodes in the U.S. during 2017 as per the records of the National Institute of mental health (NIMH). The occurrence rate is greater in adults aged 18 to 25 years. Therefore, with high-stress conditions because of several socioeconomic factors and significant spending ability within this range, the segment is expected to flourish considerably during the forecast period. 

Restraints/Challenges

• Unavailability of treatment options

Lack of specific treatments and therapies for neurasthenia treatment that do not lead to favorable outcomes is likely to hamper the market growth. The current neurasthenia treatment options focus on several therapies and antidepressants. Thus, specified treatment options that help the patients' exact improvement are necessary.

• Lack of patient awareness

Lack of awareness about anxiety can serve as a restraining factor for the market. Many people are not aware of the fact that they are suffering from anxiety or depression and tend to ignore it and thus as a result, the patients are deprived of the treatment process. This can hamper the market growth.

This neurasthenia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurasthenia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Neurasthenia Treatment Market Scope

The neurasthenia treatment market is segmented on the basis of symptoms, clinical feature, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Depression
• Anxiety
• Others

Clinical Feature

• Physical
• Mental Fatigue

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Neurasthenia Treatment Market Regional Analysis/Insights

The neurasthenia treatment market is analyzed and market size insights and trends are provided by symptoms, clinical feature, distribution channel and end-user as referenced above.

The major countries covered in the neurasthenia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to rise in the prevalence of the disease, rise in the healthcare affordability in the U.S. and rise in the knowledge and awareness amongst the people in this region

Asia-Pacific dominates the market due to an increased prevalence of fatigue and depression.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Neurasthenia Treatment Market Share Analysis

The neurasthenia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neurasthenia treatment market.

Key players operating in the neurasthenia treatment market include:

• Johnson & Johnson Services, Inc. (U.S.)
• COOPERSURGICAL, INC (U.S.)
• MEDGYN PRODUCTS, INC (U.S.)
• Thomas Medical. (U.S.)
• Smiths Group plc (U.K.)
• Panpac Medical Corp (Taiwan)
• Personal Medical Corp. (U.S.)
• Boston Scientific Corporation (U.S.)
• Coloplast Pvt. Ltd (India)
• Cook (U.S.)
• Integra LifeSciences (U.S.)
• medesign IC GmbH (Germany)
• Medtronic (Ireland)

SKU-63567